Expression and functional characterization of recombinant human HDAC1 and HDAC3

Life Sciences

Volumn 74, Issue 22, 2004, Pages 2693-2705

  Li, Junling ^a   Staver, Michael J ^a   Curtin, Michael L ^a   Holms, James H ^a   Frey, Robin R ^a   Edalji, Rohinton ^a   Smith, Richard ^a   Michaelides, Mike R ^a   Davidsen, Steven K ^a   Glaser, Keith B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Affinity purification; Chromatin remodeling; Corepressor complexes; Histone deacetylase (HDAC); Inhibitor selectivity; Recombinant enzyme

Indexed keywords

ENZYME INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; MS 27275; UNCLASSIFIED DRUG; VORINOSTAT;

ADENOCARCINOMA; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA VECTOR; DRUG SELECTIVITY; EMBRYO CELL; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME DEGRADATION; ENZYME PURIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; KIDNEY CELL; MAMMAL CELL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL DIVISION; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HELA CELLS; HISTONE DEACETYLASES; HUMANS; MULTIENZYME COMPLEXES; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; TRANSFECTION;

MAMMALIA; PICHIA; UNIDENTIFIED BACULOVIRUS;

EID: 12144287528     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.09.070     Document Type: Article

References (34)

1. Blagosklonny M.V., Robey R., Sackett D.L., Du L., Traganos F., Darzynkiewicz Z., Fojo T., Bates S.E. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Molecular Cancer Therapeutics. 1:2002;937-942.
2. Condreay J.P., Witherspoon S.M., Clay W.C., Kost T.A. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proceedings of the National Academy of Sciences of the United States of America. 96(1):1999;127-132.
3. Emiliani S., Fischle W., van Lint C., Alabed Y., Verdin E. Characterization of a human RPD3 ortholog, HDAC3. Proceedings of the National Academy of Sciences of the United States of America. 95(6):1998;2795-2800.
4. Fischle W., Dequiedt F., Hendzel M.J., Guenther M.G., Lazar M.A., Voelter W., Verdin E. Enzymatic activity associated with class-II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Molecular Cell. 9(1):2002;45-57.
5. Fischle W., Emiliani S., Hendzel M.J., Nagase T., Nomura N., Voelter W., Verdin E. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. Journal of Biological Chemistry. 274(17):1999;11713-11720.
6. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Molecular Cancer Therapeutics. 2:2003;151-163.
7. Grignani F., Dematteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F.F., Zamir I., Seiser C., Lazar M.A., Minucci S., Pelicci P.G. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 391(6669):1998;815-818.
8. Grozinger C.M., Hassig C.A., Schreiber S.L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proceedings of the National Academy of Sciences of the United States of America. 96(9):1999;4868-4873.
9. Guarente L. Sir2 links chromatin silencing, metabolism, and aging [Editorial Material]. Genes and Development. 14(9):2000;1021-1026.
10. Guenther M.G., Barak O., Lazar M.A. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase-3. Molecular and Cellular Biology. 21(18):2001;6091-6101.
11. Guenther M.G., Lane W.S., Fischle W., Verdin E., Lazar M.A., Shiekhattar R. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes and Development. 14(9):2000;1048-1057.
12. He L.Z., Guidez F., Tribioli C., Peruzzi D., Ruthardt M., Zelent A., Pandolfi P.P. Distinct interactions of PML-RAR-alpha and PLZF-RAR-alpha with co-repressors determine differential responses to RA in APL. Nature Genetics. 18(2):1998;126-135.
13. Huang Y.H., Tan M.J., Gosink M., Wang K.K.W., Sun Y. Histone deacetylase-5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Research. 62(10):2002;2913-2922.
14. Imai S.-I., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 403(6771):2000;795-800.
15. Johnstone R. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev. 1:2002;287-299.
16. Kao H.Y., Downes M., Ordentlich P., Evans R.M. Isolation of a novel histone deacetylase reveals that class-I and class-II deacetylases promote SMRT-mediated repression. Genes and Development. 14(1):2000;55-66.
17. Kelly W., O'Connor O., Marks P. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs. 11(12):2002;1695-1713.
18. Landry J., Sutton A., Tafrov S.T., Heller R.C., Stebbins J., Pillus L., Sternglanz R. The silencing protein SIR2 and its homologs are MAD-dependent protein deacetylases. Proceedings of the National Academy of Sciences of the United States of America. 97(11):2000;5807-5811.
19. Lechner T., Carrozza M.J., Yu Y.X., Grant P.A., Eberharter A., Vannier D., Brosch G., Stillman D.J., Shore D., Workman J.L. Sds3 (suppressor of defective silencing-3) is an integral component of the yeast Sin3/Rpd3 histone deacetylase complex and is required for histone deacetylase activity. Journal of Biological Chemistry. 275(52):2000;40961-40966.
20. Li J. Inhibition of growth of human oral cancer cells by transfection of MnSOD cDNA. College of Medicine, Radiation Oncology. 1995;39 The University of Iowa, Iowa.
21. Lin R.J., Nagy L., Inoue S., Shao W.L., Miller W.H., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 391(6669):1998;811-814.
22. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors. Inducers of differentiation or apoptosis of transformed cells [Review]. Journal of the National Cancer Institute. 92(15):2000;1210-1216.
23. Miska E.A., Karlsson C., Langley E., Nielsen S.J., Pines J., Kouzarides T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO Journal. 18(18):1999;5099-5107.
24. Moazed D. Enzymatic activities of Sir2 and chromatin silencing [Review]. Current Opinion in Cell Biology. 13(2):2001;232-238.
25. Ruijter Ad., Gennip Av., Caron H., Kemp S., Kuilenburg Av. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370:2003;737-749.
26. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in-vivo antitumor activity against human tumors. Proceedings of the National Academy of Sciences of the United States of America. 96(8):1999;4592-4597.
27. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning, a laboratory Manual. second ed. 1989;Cold Spring Harbor Laboratory Press, Plainville, NY.
28. Taunton J., Hassig C.A., Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator RPD3p. Science. 272(5260):1996;408-411.
29. Verdel A., Khochbin S. Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation- dependent chromatin modifiers. Journal of Biological Chemistry. 274(4):1999;2440-2445.
30. Wade P.A. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Human Molecular Genetics. 10(7, Special Issue):2001;693-698.
31. Wade P.A., Pruss D., Wolffe A.P. Histone acetylation. Chromatin in action [Review]. Trends in Biochemical Sciences. 22(4):1997;128-132.
32. Warrell R.P., He L.Z., Richon V., Calleja E., Pandolfi P.P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. Journal of the National Cancer Institute. 90(21):1998;1621-1625.
33. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in-vivo and in-vitro by trichostatin-A. Journal of Biological Chemistry. 265(28):1990;17174-17179.
34. Zhang Y., Ng H.H., Erdjument-Bromage H., Tempst P., Bird A., Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes and Development. 13(15):1999;1924-1935.